Back to Newsroom
StemCells, Inc. Completes Enrollment of First Cohort in Phase II Pathway Study for Cervical Spinal Cord Injury
Proof-of-Concept Study Designed to Measure Improvement in Motor Function
NEWARK, Calif., April 16, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for treating diseases of the central nervous system with high unmet medical need, announced today that it has completed transplanting the six patients comprising the first cohort of its Phase II Pathway®
Study. The first cohort is an open-label dose escalation arm to determine the cell dose to be used for the second cohort of the study. The second cohort of the study is a single-blind arm in 40 patients that will assess efficacy of the Company’s proprietary HuCNS-SC®
(purified human neural stem cells) platform technology for the treatment of cervical spinal cord injury (SCI).
Click here to read more